1 | days | 67,551 |
2 | weekdays | 90 |
3 | days/month | 69 |
4 | workdays | 46 |
5 | alpha-hydroxylase | 17 |
6 | d.p.i | 14 |
7 | doses/week | 13 |
8 | fractions/week | 8 |
9 | grains/m³ | 8 |
10 | alpha-hydroxycholesterol | 7 |
11 | schooldays | 7 |
12 | beta-hydroxycholesterol | 5 |
13 | migraines/month | 5 |
14 | backboards | 4 |
15 | hens/cage | 4 |
16 | uti/year | 4 |
17 | μmol/d | 4 |
18 | episodes/month | 3 |
19 | g+nes | 3 |
20 | million/year | 3 |
21 | ml/times | 3 |
22 | vancomycin/teicoplanin | 3 |
23 | μg/minute | 3 |
24 | μmol/l/h | 3 |
25 | alendronate/calcium | 2 |
26 | alpha-demethylation | 2 |
27 | alpha-hydroxy-4-cholesten-3-one | 2 |
28 | am-7 | 2 |
29 | antibiotic-days | 2 |
30 | fr. | 2 |
31 | hr/d | 2 |
32 | met-h | 2 |
33 | mrads | 2 |
34 | nonurologists | 2 |
35 | on/7 | 2 |
36 | pm-7 | 2 |
37 | puffs/week | 2 |
38 | re-coarctation | 2 |
39 | re-insertions | 2 |
40 | redos | 2 |
41 | rfus | 2 |
42 | rule-related | 2 |
43 | ser-1179 | 2 |
44 | t-3t | 2 |
45 | taxa/cultivars | 2 |
46 | 075.0 | 1 |
47 | 1/minute | 1 |
48 | 10.7-h | 1 |
49 | 131.7±3 | 1 |
50 | 21-09-06 | 1 |
51 | 439.6 | 1 |
52 | 55.1+/-21.7 | 1 |
53 | 65.1+/-33.8 | 1 |
54 | 8-heteroaryl | 1 |
55 | ab0-incompatible | 1 |
56 | acarines | 1 |
57 | acei-control | 1 |
58 | admission/presentation | 1 |
59 | aimags/provinces | 1 |
60 | alpha-1-microglobulin=20.88 | 1 |
61 | alpha-demethylase | 1 |
62 | alpha-methoxycephem | 1 |
63 | am-3 | 1 |
64 | arb-control | 1 |
65 | august,2013 | 1 |
66 | bibs® | 1 |
67 | bouts/sow | 1 |
68 | caeserotomy | 1 |
69 | caregivers/parents | 1 |
70 | central-line-days | 1 |
71 | chikv+ves | 1 |
72 | completed/group | 1 |
73 | con-trols | 1 |
74 | d-10623 | 1 |
75 | d/cycle | 1 |
76 | days,10 | 1 |
77 | days-'earlier | 1 |
78 | days/pattern | 1 |
79 | effectsize | 1 |
80 | esophagogastroduodenoscopies | 1 |
81 | fr-equivalent | 1 |
82 | h.wk | 1 |
83 | hsp70-upregulation | 1 |
84 | hydroxy-3-methylglytary | 1 |
85 | kdhsp | 1 |
86 | l.kg-1.min-1 | 1 |
87 | laarps | 1 |
88 | male+/female- | 1 |
89 | mallophagans | 1 |
90 | mcg+drospirenone | 1 |
91 | mcg/drsp | 1 |
92 | mgh2o.l | 1 |
93 | micrograms/cc | 1 |
94 | microl/mouse/day | 1 |
95 | min/run | 1 |
96 | mutation-carriers | 1 |
97 | n-benzylamine | 1 |
98 | nag=18.99 | 1 |
99 | noncommercially | 1 |
100 | normoresponsive | 1 |
101 | off-days | 1 |
102 | oryzomys | 1 |
103 | participants/mo | 1 |
104 | patient-cohort | 1 |
105 | persons/day | 1 |
106 | pyrrorophya | 1 |
107 | qbals | 1 |
108 | rapns | 1 |
109 | re-revisions | 1 |
110 | scaiii | 1 |
111 | sites/subject | 1 |
112 | spring-type | 1 |
113 | sub-functions | 1 |
114 | t-lymphocytes/mm | 1 |
115 | tunings | 1 |
116 | values/patient | 1 |
117 | years-old-patient | 1 |
118 | °c/in | 1 |
119 | ±2.56 | 1 |
1 | 075.0 | 1 |
2 | 1/minute | 1 |
3 | 10.7-h | 1 |
4 | 131.7±3 | 1 |
5 | 21-09-06 | 1 |
6 | 439.6 | 1 |
7 | 55.1+/-21.7 | 1 |
8 | 65.1+/-33.8 | 1 |
9 | 8-heteroaryl | 1 |
10 | ab0-incompatible | 1 |
11 | acarines | 1 |
12 | acei-control | 1 |
13 | admission/presentation | 1 |
14 | aimags/provinces | 1 |
15 | alendronate/calcium | 2 |
16 | alpha-1-microglobulin=20.88 | 1 |
17 | alpha-demethylase | 1 |
18 | alpha-demethylation | 2 |
19 | alpha-hydroxy-4-cholesten-3-one | 2 |
20 | alpha-hydroxycholesterol | 7 |
21 | alpha-hydroxylase | 17 |
22 | alpha-methoxycephem | 1 |
23 | am-3 | 1 |
24 | am-7 | 2 |
25 | antibiotic-days | 2 |
26 | arb-control | 1 |
27 | august,2013 | 1 |
28 | backboards | 4 |
29 | beta-hydroxycholesterol | 5 |
30 | bibs® | 1 |
31 | bouts/sow | 1 |
32 | caeserotomy | 1 |
33 | caregivers/parents | 1 |
34 | central-line-days | 1 |
35 | chikv+ves | 1 |
36 | completed/group | 1 |
37 | con-trols | 1 |
38 | d-10623 | 1 |
39 | d.p.i | 14 |
40 | d/cycle | 1 |
41 | days | 67,551 |
42 | days,10 | 1 |
43 | days-'earlier | 1 |
44 | days/month | 69 |
45 | days/pattern | 1 |
46 | doses/week | 13 |
47 | effectsize | 1 |
48 | episodes/month | 3 |
49 | esophagogastroduodenoscopies | 1 |
50 | fr-equivalent | 1 |
51 | fr. | 2 |
52 | fractions/week | 8 |
53 | g+nes | 3 |
54 | grains/m³ | 8 |
55 | h.wk | 1 |
56 | hens/cage | 4 |
57 | hr/d | 2 |
58 | hsp70-upregulation | 1 |
59 | hydroxy-3-methylglytary | 1 |
60 | kdhsp | 1 |
61 | l.kg-1.min-1 | 1 |
62 | laarps | 1 |
63 | male+/female- | 1 |
64 | mallophagans | 1 |
65 | mcg+drospirenone | 1 |
66 | mcg/drsp | 1 |
67 | met-h | 2 |
68 | mgh2o.l | 1 |
69 | micrograms/cc | 1 |
70 | microl/mouse/day | 1 |
71 | migraines/month | 5 |
72 | million/year | 3 |
73 | min/run | 1 |
74 | ml/times | 3 |
75 | mrads | 2 |
76 | mutation-carriers | 1 |
77 | n-benzylamine | 1 |
78 | nag=18.99 | 1 |
79 | noncommercially | 1 |
80 | nonurologists | 2 |
81 | normoresponsive | 1 |
82 | off-days | 1 |
83 | on/7 | 2 |
84 | oryzomys | 1 |
85 | participants/mo | 1 |
86 | patient-cohort | 1 |
87 | persons/day | 1 |
88 | pm-7 | 2 |
89 | puffs/week | 2 |
90 | pyrrorophya | 1 |
91 | qbals | 1 |
92 | rapns | 1 |
93 | re-coarctation | 2 |
94 | re-insertions | 2 |
95 | re-revisions | 1 |
96 | redos | 2 |
97 | rfus | 2 |
98 | rule-related | 2 |
99 | scaiii | 1 |
100 | schooldays | 7 |
101 | ser-1179 | 2 |
102 | sites/subject | 1 |
103 | spring-type | 1 |
104 | sub-functions | 1 |
105 | t-3t | 2 |
106 | t-lymphocytes/mm | 1 |
107 | taxa/cultivars | 2 |
108 | tunings | 1 |
109 | uti/year | 4 |
110 | values/patient | 1 |
111 | vancomycin/teicoplanin | 3 |
112 | weekdays | 90 |
113 | workdays | 46 |
114 | years-old-patient | 1 |
115 | °c/in | 1 |
116 | ±2.56 | 1 |
117 | μg/minute | 3 |
118 | μmol/d | 4 |
119 | μmol/l/h | 3 |
1 | male+/female- | 1 |
2 | fr. | 2 |
3 | 075.0 | 1 |
4 | days,10 | 1 |
5 | l.kg-1.min-1 | 1 |
6 | am-3 | 1 |
7 | august,2013 | 1 |
8 | d-10623 | 1 |
9 | 131.7±3 | 1 |
10 | 439.6 | 1 |
11 | 21-09-06 | 1 |
12 | ±2.56 | 1 |
13 | am-7 | 2 |
14 | pm-7 | 2 |
15 | 55.1+/-21.7 | 1 |
16 | on/7 | 2 |
17 | 65.1+/-33.8 | 1 |
18 | alpha-1-microglobulin=20.88 | 1 |
19 | ser-1179 | 2 |
20 | nag=18.99 | 1 |
21 | pyrrorophya | 1 |
22 | micrograms/cc | 1 |
23 | μmol/d | 4 |
24 | hr/d | 2 |
25 | rule-related | 2 |
26 | hens/cage | 4 |
27 | ab0-incompatible | 1 |
28 | d/cycle | 1 |
29 | n-benzylamine | 1 |
30 | alpha-hydroxy-4-cholesten-3-one | 2 |
31 | mcg+drospirenone | 1 |
32 | spring-type | 1 |
33 | alpha-demethylase | 1 |
34 | alpha-hydroxylase | 17 |
35 | 1/minute | 1 |
36 | μg/minute | 3 |
37 | normoresponsive | 1 |
38 | effectsize | 1 |
39 | 10.7-h | 1 |
40 | met-h | 2 |
41 | μmol/l/h | 3 |
42 | episodes/month | 3 |
43 | migraines/month | 5 |
44 | days/month | 69 |
45 | d.p.i | 14 |
46 | scaiii | 1 |
47 | doses/week | 13 |
48 | puffs/week | 2 |
49 | fractions/week | 8 |
50 | h.wk | 1 |
51 | mgh2o.l | 1 |
52 | alpha-hydroxycholesterol | 7 |
53 | beta-hydroxycholesterol | 5 |
54 | arb-control | 1 |
55 | acei-control | 1 |
56 | 8-heteroaryl | 1 |
57 | alpha-methoxycephem | 1 |
58 | t-lymphocytes/mm | 1 |
59 | alendronate/calcium | 2 |
60 | °c/in | 1 |
61 | vancomycin/teicoplanin | 3 |
62 | hsp70-upregulation | 1 |
63 | alpha-demethylation | 2 |
64 | re-coarctation | 2 |
65 | admission/presentation | 1 |
66 | days/pattern | 1 |
67 | min/run | 1 |
68 | participants/mo | 1 |
69 | kdhsp | 1 |
70 | mcg/drsp | 1 |
71 | completed/group | 1 |
72 | uti/year | 4 |
73 | million/year | 3 |
74 | days-'earlier | 1 |
75 | mrads | 2 |
76 | backboards | 4 |
77 | aimags/provinces | 1 |
78 | esophagogastroduodenoscopies | 1 |
79 | ml/times | 3 |
80 | g+nes | 3 |
81 | acarines | 1 |
82 | chikv+ves | 1 |
83 | tunings | 1 |
84 | qbals | 1 |
85 | con-trols | 1 |
86 | mallophagans | 1 |
87 | re-revisions | 1 |
88 | sub-functions | 1 |
89 | re-insertions | 2 |
90 | rapns | 1 |
91 | redos | 2 |
92 | laarps | 1 |
93 | taxa/cultivars | 2 |
94 | mutation-carriers | 1 |
95 | caregivers/parents | 1 |
96 | nonurologists | 2 |
97 | rfus | 2 |
98 | days | 67,551 |
99 | antibiotic-days | 2 |
100 | central-line-days | 1 |
101 | off-days | 1 |
102 | weekdays | 90 |
103 | workdays | 46 |
104 | schooldays | 7 |
105 | oryzomys | 1 |
106 | t-3t | 2 |
107 | sites/subject | 1 |
108 | years-old-patient | 1 |
109 | values/patient | 1 |
110 | fr-equivalent | 1 |
111 | patient-cohort | 1 |
112 | bouts/sow | 1 |
113 | microl/mouse/day | 1 |
114 | persons/day | 1 |
115 | noncommercially | 1 |
116 | caeserotomy | 1 |
117 | hydroxy-3-methylglytary | 1 |
118 | bibs® | 1 |
119 | grains/m³ | 8 |